CKAP4 and hepatocellular carcinoma: Moreover, anti-CKAP4 antibodies inhibited HCC growth and reduced HCC tumor size and weight [19,42], while their anti-tumor effects were significantly enhanced when combined with lenvatinib, a multikinase inhibitor commonly used in HCC treatment [19].